Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience

BACKGROUND: Imatinib mesylate is the cornerstone therapy in the management of chronic myeloid leukemia (CML). Monitoring of adverse drug reactions (ADRs) of imatinib in our patients is very important to ensure their safety. Aims and Objectives: The current study aims to monitor ADRs encountered in C...

Descripción completa

Detalles Bibliográficos
Autores principales: Swain, Trupti Rekha, Goutam, Siddhartha, Jena, Rabindra Kumar, Rout, Niranjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846910/
https://www.ncbi.nlm.nih.gov/pubmed/36537404
http://dx.doi.org/10.4103/ijp.ijp_844_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846910/
https://www.ncbi.nlm.nih.gov/pubmed/36537404
http://dx.doi.org/10.4103/ijp.ijp_844_21

Ejemplares similares